$1.750
+0.117 (+6.71%)收盤時
- 最高
- 1.790
- 開盤
- 1.700
- 成交量加權均價
- 1.73
- 成交量
- 9.80K
- 市值
- —
- 最低
- 1.650
- 成交金額
- 16.95K
- 企業價值/稅息折舊攤銷前利潤（TTM）
- 0.00
Propanc Biopharma, Inc. is an Australia-based biopharmaceutical company. The Company is focused on the development of novel cancer treatments for patients suffering from pancreatic, ovarian and colorectal cancers. The Company has developed a rational, composite formulation of anti-cancer compounds, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its lead product candidate, PRP, is a variation upon its formulation and involves pro-enzymes, the inactive precursors of enzymes. PRP is a long-term therapy based on pancreatic proenzyme formulation to prevent tumor recurrence and metastasis. PRP is a patented, formulation consisting of two proenzymes mixed in a synergetic ratio. PRP is in the preclinical phase of development. Its drug pipeline also includes POP1.
AI 分析 of Propanc Biopharma Inc (PPCB)
賣出Propanc Biopharma Inc (PPCB) is not a good buy right now. The current price is $1.75, which is significantly down 98.78% year-to-date and 99.22% over the past year. The RSI is at 27.15, indicating that the stock is oversold, but the forward P/E ratio is 0, suggesting no earnings growth is expected in the near future. The main risk is the company's negative net income, which reached -$63,603,336 in Q3 2025, indicating ongoing financial struggles.
估值指標
事件時間軸
資訊
9.011-02NewsfilterPropanc Biopharma Announces New Preclinical Findings on Cancer Treatment
- 8.510-30Newsfilter
Propanc Biopharma Advances PPC-001 Clinical Study Preparations
- 8.510-28Newsfilter
Propanc Biopharma Advances Clinical Development for PPC-001
- 9.010-26Newsfilter
Propanc Biopharma Reveals New Data Supporting PRP's Potential Against Chemotherapy Resistance
- 8.510-22Newsfilter
Propanc Biopharma Announces 1-for-10 Reverse Stock Split to Meet Nasdaq Compliance
PPCB 常見問題 —— 由 Alphio AI 解答
Propanc Biopharma, Inc. is an Australia-based biopharmaceutical company. The Company is focused on the development of novel cancer treatments for patients suffering from pancreatic, ovarian and colorectal cancers. The Company has developed a rational, composite formulation of anti-cancer compounds, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its lead product candidate, PRP, is a variation upon its formulation and involves pro-enzymes, the inactive precursors of enzymes. PRP is a long-term therapy based on pancreatic proenzyme formulation to prevent tumor recurrence and metastasis. PRP is a patented, formulation consisting of two proenzymes mixed in a synergetic ratio. PRP is in the preclinical phase of development. Its drug pipeline also includes POP1. It operates in the Healthcare sector.
Propanc Biopharma Inc (PPCB) is not a good buy right now. The current price is $1.75, which is significantly down 98.78% year-to-date and 99.22% over the past year. The RSI is at 27.15, indicating that the stock is oversold, but the forward P/E ratio is 0, suggesting no earnings growth is expected in the near future. The main risk is the company's negative net income, which reached -$63,603,336 in Q3 2025, indicating ongoing financial struggles.
社群
更多 ↗暫無貼文
註冊或登入後參與討論相關文章
- CPI Report and the Stock Market: How to Read October 2026 Inflation Data Before the Fed DecidesOctober 2026 CPI lands Nov 10 with no year-over-year number and Fed hike odds near 80%. Learn how to read CPI, which stocks react, and how to plan for it.
- Are You Buying NVIDIA’s Earnings or Its CEO’s Perfect Image?An Alphio analysis of NVIDIA’s share-price timeline, operating results, governance uncertainty and upcoming earnings.
- Stock Market After the 2026 Midterms: What a Democratic Congress Means for InvestorsDemocrats swept Congress in the 2026 midterms. See how stocks reacted, what history says about post-midterm returns, and which sectors face new risks.
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。